Nicholas Saraceno, Senior Editor

The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.

In this Pharmaceutical Commerce video interview, Blake Powers, CEO of Medigi, discusses his first byline with the publication, along with why the industry may be stuck in its ways in certain aspects.

Webinar dives into the trends, technology, and market necessities that can help tackle these obstacles.

The company’s European Hub facility in Roermond is expanding by over 235,000 square feet, and will be dedicated to accommodating freezer farm capacity.

A retrospective cohort study investigates the characteristics of female patients with localized breast cancer that are associated with this nonpersistence.

The 53,000 square-foot facility is expected to become a Northeastern biotech hub, and will be home to various CGT services.

The $530 million investment will accelerate the company’s development and production process for therapies in the rare disease space.

A cohort study explores the connection between the rise in Medicare Advantage plan coverage and enrollee satisfaction.

Beneath all the “organized chaos,” industry shows such as LogiPharma Europe spotlight the valuable opportunity offered by these events to further educate our most valuable asset: our readers.

LogiPharma Europe captured many timely topics, including the importance of next-level approaches in aligning temperature-controlled transit and visibility.

The company's latest service provides risk and quality management for the pharma and healthcare sectors.

Causal mediation analysis sought to determine how public hesitancy plays a role in the government procurement of certain vaccines.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Lung-I Cheng, PhD, VP, Head of Cell & Gene Therapy Service Line, Cencora, offers his thoughts on industry pain points and where he envisions the market progressing in terms of its technological capabilities.

Ashfield Event Experiences and WRG merge in an effort to better serve the healthcare industry.

The development and manufacturing plant will be constructed in Texas, and is expected to become operational by Q1 2025.

The new plant in Italy is expected to tackle the rise in biopharmaceutical material demand, specifically for GLP-1s.

A retrospective study explores the connection between adherence and racial/ethnic disparities among patients with Alzheimer’s disease, along with similar dementias.

The Netherlands plant is expected to provide solutions that can help further the development of advanced therapies.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Lung-I Cheng, PhD, VP, Head of Cell & Gene Therapy Service Line, Cencora offers his thoughts on Cencora's inaugural ThinkLive Cell and Gene Therapy Summit.

Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.

According to the IATA, the streak continues—April represents the fifth consecutive month of positive development.

The Texas facility helps meet the cross-border logistics demand created by nearshoring.

The SSC strives to simply and add efficiencies to the scheduling technology used by the logistics sector.

Among its benefits, the fund will provide up to $8,000 in medication copayment or insurance premium assistance.

The transaction serves as way to expand customers’ access to products and capabilities.

The deal grows it pipeline, powered by panCAR programs in autoimmune disease and oncology.

With the acquisition, Merck’s US and Canada life science business aims to further increase its viral vector manufacturing capabilities.

The CDMO will run the active pharmaceutical ingredient pilot plant in Sandwich, UK, along with development laboratories.

The deal features felzartamab, an investigational anti-CD38 monoclonal antibody, whose clinical outcomes have shown potential to tackle various immune-mediated diseases.

The document reiterates the company’s commitment to ESG principles, including carbon neutrality by 2030.